Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Indian Drug Companies Increasingly Active In Global M&A

This article was originally published in The Pink Sheet Daily

Executive Summary

Subcontinent’s pharmaceutical companies are “getting very ambitious,” Ranbaxy exec tells “The Pink Sheet” DAILY.

You may also be interested in...

Indian Companies Ramping Up For Follow-On Biologics

Indian pharma firms are expected to be active in filing for biosimilar approvals, Ranbaxy exec tells “The Pink Sheet” DAILY

GSK/Ranbaxy Deal Gives Indian Firm Greater Development Charge

Under expansion of 2003 deal, Indian firm will take targets to proof of concept, gaining milestones, possible royalties.

Generic Drug Firms Look To Bulk Up With Addition Of Merck KGaA’s Generics Unit

Ranbaxy and Actavis are among the generic drug companies interested in bidding for the $2.32 billion business.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts